reports
Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeuti...
Brooklyn ImmunoTherapeutics Announces Name Change to Eterna Therapeutics and Provides Corporate Updates New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company’s shares to trade under new ticker symbol “ERNA” starting on October 17, 2022, and a one-for-twenty share consolidation will become effective on that date SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeuti...
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-...
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity. The primary endpoint of the study was to estimate 2-year Event-Free Survival (EFS) with key secondary endpoints of Overall Survival (OS) and safety of IRX-2. One hundred and fifty patients were enrolled ...
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification R...
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today announced that on June 17, 2022, it received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company is not in compliance with the minimum bid price requirement ("Minimum Bid Requirement") of US$1.00 per share under the Nasdaq...
Brooklyn ImmunoTherapeutics Announces Board Changes
Brooklyn ImmunoTherapeutics Announces Board Changes SAN DIEGO, June 07, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the following appointments to the Board, effective June 5, 2022: Matt Angel, Ph.D., Interim Chief Executive Officer (“CEO”) of Brooklyn and Co-Founder, Chairman, President and CEO of Factor Bioscience Inc.Gregory Fiore, Co-Fo...
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management:...
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chai...
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Re...
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q SAN DIEGO, May 27, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”), stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended...
Brooklyn ImmunoTherapeutics Announces Establishment of New Research an...
Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines Company has expanded team with scientific hires who hold research expertise in stem cells, synthetic RNA, nanoparticle delivery systems and immunology SAN DIEGO, April 21, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced...
Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 202...
Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results SAN DIEGO, April 15, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the fourth quarter and year ended December 31, 2021. Financial and corporate highlights for the quarter and year months ended December 31, 2021 and subsequently include the following: Fourth quarter end...
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private P...
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it has closed its previously announced private placement with a leading healthcare investor. The gross proceeds to Brooklyn from the private placement, before deducting the placement agent’s fees and o...
Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement
Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it has entered into a definitive agreement to sell securities in a private placement with a leading healthcare investor. The gross proceeds to Brooklyn from the private placement, before deducting the placement a...
Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Re...
Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company’s Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (servi...
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine I...
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that 18 new patents were issued and 17 new patent applications were filed in 2021. The intellectual property is owned by Factor Bioscience (“Factor”) and exclusively licensed to Brooklyn for various fields of therape...
Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index
Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that Brooklyn has been added to the ICE Biotechnology Index (NYSE:ICEBIO) following the December 20, 2021 reconstitution. “The continued recognition of Brooklyn among key biotechnology indices is encouraging and we continue to believe that our value proposi...
Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index
Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that Brooklyn has been named to be part of the Nasdaq Biotechnology Index (Nasdaq:NBI), effective December 20, 2021. “We are very proud to represent the biotech sector as part of the Nasdaq Biotechnology Index. We believe our approach and our technology ...
Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Confer...
Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that President and CEO Howard Federoff, M.D., Ph.D. is scheduled to present at the following virtual conferences: Benzinga Global Small Cap Conference: December 8 – 9, 2021 Dr. Federoff will deliver his corporate presentation on Wednesday, D...
Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice Presiden...
Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Quality Company Continues to Secure Resources to Build Gene Editing/Cell Therapy Drug Development Platform NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of Susan McClatchey as Vice President, Head of Quality. “We are aggressively preparing to handle what we beli...
Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement...
Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Secondary Offering of Shares Issued in Previously Announced Novellus Acquisition NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”) today announced that on November 18, 2021 it filed with the Securities and Exchange Commission a registration statement on Form S-1 relating to the proposed public offering by certain selling stockholders of up to 6,281,454 shares of Brooklyn’s common stock received in connection with Brooklyn’s acquisition of Novellus, Inc...
Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Res...
Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- . (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the quarter ended September 30, 2021. Financial and corporate highlights for the quarter ended September 30, 2021 and subsequently include the following: Transitioned from the NYSE American to the Nasdaq Global Market t...
Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq
Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq Ticker Symbol to Remain “BTX” NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- . (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced it will transfer its common stock listing from the NYSE American to the Nasdaq Global Market, effective upon the market close on October 22, 2021. Brooklyn’s common stock is expected to begin trading as a Nasdaq...
Brooklyn ImmunoTherapeutics Reports Inducement Grants
Brooklyn ImmunoTherapeutics Reports Inducement Grants NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that on September 20, 2021, Roger Sidhu was granted a non-qualified stock option covering 161,300 shares of Brooklyn’s common stock (the “Time-Based Option”) and a restricted stock unit covering 80,650 shares of Brooklyn’s co...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.